MYB

Summary

MYB (MYB proto-oncogene, transcription factor, HGNC:7545) is a protein-coding gene on chromosome 6q23.3, encoding Transcriptional activator Myb (P10242). Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5’-YAAC[GT]G-3’. It is a selective cancer dependency (DepMap: 16.5% of cell lines).

This gene encodes a protein with three HTH DNA-binding domains that functions as a transcription regulator. This protein plays an essential role in the regulation of hematopoiesis. This gene may be aberrently expressed or rearranged or undergo translocation in leukemias and lymphomas, and is considered to be an oncogene. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 4602 — RefSeq curated summary.

At a glance

• GWAS associations: 85
• Clinical variants (ClinVar): 104 total — 3 pathogenic
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 16.5% of screened cell lines
• Transcription factor: yes — 198 downstream targets (CollecTRI)
• MANE Select transcript: NM_001130173

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7545
Approved symbol	MYB
Name	MYB proto-oncogene, transcription factor
Location	6q23.3
Locus type	gene with protein product
Status	Approved
Aliases	c-myb
Ensembl gene	ENSG00000118513
Ensembl biotype	protein_coding
OMIM	189990
Entrez	4602

Gene structure

Transcript identifiers

Ensembl transcripts: 43 — 26 nonsense_mediated_decay, 15 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000339290, ENST00000341911, ENST00000367812, ENST00000367814, ENST00000420123, ENST00000430686, ENST00000438901, ENST00000442647, ENST00000463282, ENST00000524588, ENST00000525002, ENST00000525369, ENST00000525477, ENST00000525514, ENST00000525940, ENST00000526187, ENST00000526320, ENST00000526565, ENST00000526889, ENST00000527615, ENST00000528015, ENST00000528140, ENST00000528343, ENST00000528345, ENST00000528774, ENST00000529262, ENST00000529297, ENST00000529586, ENST00000531519, ENST00000531634, ENST00000531737, ENST00000531845, ENST00000533384, ENST00000533624, ENST00000533808, ENST00000533837, ENST00000534044, ENST00000534121, ENST00000534736, ENST00000616088, ENST00000882541, ENST00000882542, ENST00000912484

RefSeq mRNA: 8 — MANE Select: NM_001130173 NM_001130172, NM_001130173, NM_001161656, NM_001161657, NM_001161658, NM_001161659, NM_001161660, NM_005375

CCDS: CCDS47481, CCDS47482, CCDS5174, CCDS55058, CCDS55059, CCDS55060, CCDS55061, CCDS55062

Canonical transcript exons

ENST00000341911 — 16 exons

Exon	Start	End
ENSE00002148640	135217864	135219172
ENSE00002169478	135185903	135186020
ENSE00003476698	135196961	135197323
ENSE00003484009	135190127	135190347
ENSE00003491863	135189791	135189883
ENSE00003505230	135200085	135200199
ENSE00003530434	135194356	135194460
ENSE00003541901	135200290	135200415
ENSE00003570876	135187834	135187905
ENSE00003584128	135193838	135193918
ENSE00003589335	135198908	135199050
ENSE00003602303	135203217	135203324
ENSE00003624826	135201639	135201749
ENSE00003644014	135195748	135196002
ENSE00003645339	135192324	135192558
ENSE00003849352	135181308	135181536

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 96.61.

FANTOM5 (CAGE): breadth broad, TPM avg 19.2271 / max 1826.3313, expressed in 783 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
69919	10.1601	556
69917	5.8298	556
69918	1.8276	298
69925	0.4077	200
204212	0.3002	91
69926	0.2837	58
69927	0.1685	63
69928	0.1326	78
204213	0.1086	50
69924	0.0085	2

Top tissues by expression

278 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of sigmoid colon	UBERON:0004993	96.61	gold quality
bronchial epithelial cell	CL:0002328	96.30	gold quality
epithelium of bronchus	UBERON:0002031	95.92	gold quality
colonic mucosa	UBERON:0000317	95.64	gold quality
trabecular bone tissue	UBERON:0002483	95.43	gold quality
bronchus	UBERON:0002185	94.50	gold quality
bone marrow	UBERON:0002371	94.23	gold quality
thymus	UBERON:0002370	94.18	gold quality
rectum	UBERON:0001052	93.70	gold quality
buccal mucosa cell	CL:0002336	91.56	gold quality
bone marrow cell	CL:0002092	90.56	gold quality
mucosa of transverse colon	UBERON:0004991	90.39	gold quality
right uterine tube	UBERON:0001302	90.38	gold quality
ileal mucosa	UBERON:0000331	87.10	gold quality
epithelium of nasopharynx	UBERON:0001951	85.68	gold quality
colonic epithelium	UBERON:0000397	85.56	gold quality
epithelium of mammary gland	UBERON:0003244	85.51	gold quality
endometrium epithelium	UBERON:0004811	85.05	gold quality
mammary duct	UBERON:0001765	84.97	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.47	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	82.27	gold quality
transverse colon	UBERON:0001157	81.10	gold quality
nasal cavity epithelium	UBERON:0005384	80.61	silver quality
duodenum	UBERON:0002114	79.99	gold quality
vermiform appendix	UBERON:0001154	79.53	gold quality
caecum	UBERON:0001153	79.43	gold quality
jejunal mucosa	UBERON:0000399	79.36	gold quality
monocyte	CL:0000576	78.76	gold quality
mammary gland	UBERON:0001911	78.56	gold quality
mononuclear cell	CL:0000842	78.39	gold quality

Single-cell (SCXA)

Detected in 7 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-150728	yes	481.84
E-ANND-3	yes	14.24
E-HCAD-1	yes	12.95
E-MTAB-6701	yes	12.37
E-CURD-114	yes	9.28
E-MTAB-10042	yes	5.99
E-MTAB-9801	no	2.83

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

198 targets.

Target	Regulation
ACOT11
ACTA2
ACTG2	Activation
ADAM2
ADIPOQ
ADRA1D
AKT1
ALOX5	Activation
AMY2A
ANK1	Activation
ANPEP	Unknown
AR	Activation
ATP2B1
ATP9B
B2M	Unknown
BCL2	Activation
BCL2L1	Activation
BCL2L11
BRCA1	Unknown
CA1	Unknown
CASP8AP2
CAT
CCNA1	Activation
CCNB1	Unknown
CCND1	Activation
CD1D	Unknown
CD34	Unknown
CD4	Repression
CD74
CD86

JASPAR motifs

Motif	Name	Family
MA0100.3	MYB	Myb/SANT domain factors
MA0100.4	MYB	Myb/SANT domain factors

JASPAR matrix evidence (PMIDs): PMID:8467793

Upstream regulators (CollecTRI, top): ARID5B, BCL3, CEBPA, CREB1, E2F1, EGR1, ESR1, ETS1, ETS2, ETV3, FOS, FOSL2, GATA1, GFI1, HBP1, HOXA9, IRF1, JUN, JUND, KAT5, LEF1, MAZ, MEIS1, MYB, MYBL2, MZF1, NFKB1, PARP1, RELB, SATB1, SP1, SPI1, SSRP1, STAT3, TAF1, TAL1, TBP, TFAP2C, TWIST1, TWIST2

miRNA regulators (miRDB)

132 targeting MYB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-545-3P	99.95	70.74	2783

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 16.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• Activation of c-MYC and c-MYB proto-oncogenes is associated with decreased apoptosis in tumor colon progression. (PMID:11848471)
• Friend murine erythroleukemia cells are held in an immature and proliferating state by a pathway that is dependent on Myb activity (PMID:11896618)
• c-Myb transactivates the IGFBP-5 promoter (PMID:11973331)
• c-Myb has no apparent effect on core binding factor/polyoma enhancer-binding protein 2 binding, but is critical for activation of enhancer-dependent transcription of the TCR delta enhancer. (PMID:12370369)
• role in regulating type I collagen alpha 2 chain gene (PMID:12424255)
• involvement of c-myb in the regulation of intestinal nutrient absorption (PMID:12529244)
• Data suggest that the negative influence on transactivation properties by the negative regulatory domain region of c-Myb depends on sumoylation sites. (PMID:12631292)
• NmU expression is related to Myb and that the NmU/NMU1R axis constitutes a previously unknown growth-promoting autocrine loop in myeloid leukemia cells (PMID:15187020)
• p53 antagonizes c-Myb by recruiting mSin3A to down-regulate specific Myb target genes (PMID:15509555)
• c-Myb activity is directly regulated by cyclin D1 and CDKs and imply that c-Myb activity is regulated during the cell cycle in hematopoietic cells (PMID:15687240)
• 10 genes were down-regulated following treatment of the T-ALL cells with 0.15 and 1.5 microg/mL of metal ores at 72 h. (PMID:15747776)
• data suggest that amplification of c-myb in tumor cells may lead to robust GRP78 gene induction, which may in turn assist cells in survival under conditions of oxygen deprivation and nutrient stress (PMID:15778089)
• c-Myb has a longer half-life (at least 2-fold) in BCR/ABL-expressing than in normal hematopoietic cells (PMID:15927960)
• EGF-induced activation of B-Myb promoter required both E2F and EGFR target sites (PMID:16299810)
• point mutation are uncommon in patients with myeloproliferative disorders (PMID:16461764)
• c-Myb is a major factor that controls differentiation as well as proliferation of hematopoietic progenitor cells derived from hemogenic endothelial cells; appropriate levels of c-Myb protein are strictly defined at distinct differentiation steps (PMID:16597594)
• Together, these results show that the cAMP pathway blocks gamma-globin gene expression in K562 cells by increasing c-Myb expression. (PMID:16631597)
• The enhanced stability of c-Myb in CML blast crisis cells and perhaps in other types of leukemia is not caused by a genetic mechanism. (PMID:16797705)
• individuals with elevated HbF levels during adult erythropoiesis demonstrated simultaneous transcriptional down-regulation in cMYB and HBS1L (PMID:16861354)
• Among MYB regulation, the most dynamic is the control of transcriptional elongation by sequences within intron 1, this regulatory sequence is transcribed into an RNA stem-loop and 19-residue polyuridine tract, and is subject to mutation in colon cancer. (PMID:16977606)
• a lack of integrin engagement leads to the induction of cellular markers associated with myeloid differentiation (PMID:17095623)
• c-Myb protein plays a previously unappreciated role in the G(2)/M cell cycle transition of normal and malignant human hematopoietic cells (PMID:17242210)
• c-Myb regulates cell cycle-associated IP3R1 transcription in VSMCs via specific highly conserved Myb-binding sites in the IP3R1 promoter. (PMID:17363689)
• Duplication of MYB is an oncogenic event and we suggest that MYB could be a therapeutic target in human T cell acute lymphoblastic leukemia. (PMID:17435759)
• The MYB(dup) alteration was associated with T-cell acute leukemia (PMID:17452517)
• Protein expression of c-Myb in human arterial vascular smooth muscle cells is stimulated by platelet-derived growth factor (PDGF). (PMID:17599807)
• MYB is an effector of estrogen/estrogen signaling (PMID:17690249)
• The HBS1L-MYB intergenic region on chromosome 6q23.3 influences erythrocyte, platelet, and monocyte counts. (PMID:17712044)
• Alu–mediated MYB tandem duplication occurs at low frequency during normal thymocyte development and is clonally selected during the molecular pathogenesis of human T-ALL (PMID:18070937)
• TRAF6 is modified by small ubiquitin-related modifier-1, interacts with histone deacetylase 1, and represses c-Myb-mediated transactivation. (PMID:18093978)
• An array of variant transcripts, expressed in highly regulated, lineage-specific patterns were formed from alternate exons 8A, 9A, 9B, 10A, 13A, & 14A. They encoded c-Myb proteins with identical DNA binding domains but unique C-terminal domains. (PMID:18195038)
• c-Myb cooperates with FLASH in foci associated with active RNA polymerase II, leading to enhancement of Myb-dependent gene activation. (PMID:18408764)
• MYB is highly expressed in almost all estrogen-receptor-positive breast tumours & is a direct target of estrogen/ER signalling. It is required for tumor cell proliferation. Review. (PMID:18476782)
• These data provide evidence that c-Myb may serve a previously unappreciated role in the coupling between transcription and splicing. (PMID:18498763)
• c-Myb is an evolutionally conserved target of miR-150 and miR-150/c-Myb interaction is important for embryonic development and possibly oncogenesis (PMID:18667440)
• restoration of c-Myb levels partly alleviates tumors suppressive effects of miR-15a/16, suggesting that c-Myb is a key downstream target of this microRNA cluster (PMID:18708755)
• Fbxw7, the F-box protein of an SCF complex, targets c-Myb for degradation in a Wnt-1- and NLK-dependent manner. (PMID:18765672)
• these findings suggest the presence of a c-Myb-miR-15a autoregulatory feedback loop of potential importance in human hematopoiesis (PMID:18818396)
• a gain of the MYB locus, was found recurrently and only in the MYST3-linked AMLs (7/18 vs 0/34). MYST3-AMLs have also a specific a gene expression profile, which includes overexpression of MYB, CD4 and HOXA genes (PMID:18818702)
• The results indicate that c-Myb potentiates Stat5a-driven gene expression, possibly functioning as a Stat5a coactivator, in human breast cancer. (PMID:19036881)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	myb	ENSDARG00000053666
mus_musculus	Myb	ENSMUSG00000019982
rattus_norvegicus	Myb	ENSRNOG00000055858

Paralogs (6): CDC5L (ENSG00000096401), MYBL2 (ENSG00000101057), TTF1 (ENSG00000125482), DMTF1 (ENSG00000135164), SNAPC4 (ENSG00000165684), MYBL1 (ENSG00000185697)

Protein

Protein identifiers

Transcriptional activator Myb — P10242 (reviewed: P10242)

Alternative names: Proto-oncogene c-Myb

All UniProt accessions (24): A0A087WTI6, A0A0C4DG19, P10242, E9PIW4, E9PJ96, E9PJF1, E9PJT2, E9PKZ3, E9PLN0, E9PMQ0, E9PMZ0, E9PN43, E9PN92, E9PNH6, E9PP87, E9PPL8, E9PPR4, E9PQQ2, H0YCN6, Q708E3, Q708E5, Q708E6, Q708E8, Q708E9

UniProt curated annotations — full annotation on UniProt →

Function. Transcriptional activator; DNA-binding protein that specifically recognize the sequence 5’-YAAC[GT]G-3’. Plays an important role in the control of proliferation and differentiation of hematopoietic progenitor cells.

Subunit / interactions. Binds MYBBP1A. Interacts with HIPK2, MAF and NLK. Binds to HIPK1.

Subcellular location. Nucleus.

Post-translational modifications. Ubiquitinated; mediated by SIAH1 and leading to its subsequent proteasomal degradation. SUMOylated by TRAF7; leading to MYB transcriptional activity inhibition. Phosphorylated by NLK on multiple sites, which induces proteasomal degradation. Phosphorylated by HIPK1. This phosphorylation reduces MYB transcription factor activity but not MYB protein levels.

Domain organisation. Comprised of 3 domains; an N-terminal DNA-binding domain, a centrally located transcriptional activation domain and a C-terminal domain involved in transcriptional repression.

Induction. Negatively regulated by microRNA-155 (miR-155).

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.

Isoforms (12)

UniProt ID	Names	Canonical?
P10242-1	1	yes
P10242-2	2
P10242-3	3
P10242-4	4
P10242-5	5
P10242-6	6
P10242-7	7
P10242-8	8
P10242-9	9
P10242-10	10
P10242-11	11
P10242-12	12

RefSeq proteins (8): NP_001123644, NP_001123645, NP_001155128, NP_001155129, NP_001155130, NP_001155131, NP_001155132, NP_005366 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001005	SANT/Myb	Domain
IPR009057	Homeodomain-like_sf	Homologous_superfamily
IPR012642	Tscrpt_reg_Wos2-domain	Domain
IPR015395	C-myb_C	Domain
IPR017930	Myb_dom	Domain
IPR050560	MYB_TF	Family

Pfam: PF00249, PF07988, PF09316

UniProt features (36 total): splice variant 12, region of interest 5, modified residue 4, domain 3, cross-link 3, sequence conflict 3, DNA-binding region 3, sequence variant 2, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P10242-F1	59.16	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (7): 471, 480, 532, 534, 480, 503, 527

Function

Pathways and Gene Ontology

Reactome pathways

15 pathways

ID	Pathway
R-HSA-8939236	RUNX1 regulates transcription of genes involved in differentiation of HSCs
R-HSA-9018519	Estrogen-dependent gene expression
R-HSA-9616222	Transcriptional regulation of granulopoiesis
R-HSA-983231	Factors involved in megakaryocyte development and platelet production
R-HSA-9834899	Specification of the neural plate border
R-HSA-109582	Hemostasis
R-HSA-1266738	Developmental Biology
R-HSA-162582	Signal Transduction
R-HSA-212436	Generic Transcription Pathway
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)
R-HSA-8878171	Transcriptional regulation by RUNX1
R-HSA-8939211	ESR-mediated signaling
R-HSA-9006931	Signaling by Nuclear Receptors
R-HSA-9758941	Gastrulation

MSigDB gene sets: 576 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, AP1_01, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, WALLACE_PROSTATE_CANCER_RACE_UP, WANG_CLIM2_TARGETS_UP, BENPORATH_ES_WITH_H3K27ME3, DORSAM_HOXA9_TARGETS_UP, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_MYELOID_CELL_DEVELOPMENT, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_RESPONSE_TO_PEPTIDE, RORA1_01, GOBP_B_CELL_ACTIVATION, FISCHER_G1_S_CELL_CYCLE

GO Biological Process (38): G1/S transition of mitotic cell cycle (GO:0000082), negative regulation of transcription by RNA polymerase II (GO:0000122), mitotic cell cycle (GO:0000278), response to hypoxia (GO:0001666), in utero embryonic development (GO:0001701), response to ischemia (GO:0002931), regulation of DNA-templated transcription (GO:0006355), calcium ion transport (GO:0006816), skeletal muscle cell proliferation (GO:0014856), stem cell division (GO:0017145), B cell differentiation (GO:0030183), erythrocyte differentiation (GO:0030218), positive regulation of collagen biosynthetic process (GO:0032967), positive regulation of neuron apoptotic process (GO:0043525), T-helper 2 cell differentiation (GO:0045064), negative regulation of megakaryocyte differentiation (GO:0045653), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), spleen development (GO:0048536), thymus development (GO:0048538), embryonic digestive tract development (GO:0048566), positive regulation of smooth muscle cell proliferation (GO:0048661), positive regulation of glial cell proliferation (GO:0060252), myeloid cell development (GO:0061515), cellular response to hydrogen peroxide (GO:0070301), cellular response to retinoic acid (GO:0071300), cellular response to interleukin-6 (GO:0071354), positive regulation of transforming growth factor beta production (GO:0071636), negative regulation of hematopoietic progenitor cell differentiation (GO:1901533), positive regulation of miRNA transcription (GO:1902895), positive regulation of hepatic stellate cell proliferation (GO:1904899), cellular response to leukemia inhibitory factor (GO:1990830), positive regulation of hepatic stellate cell activation (GO:2000491), positive regulation of testosterone secretion (GO:2000845), regulation of gene expression (GO:0010468), myeloid cell differentiation (GO:0030099), homeostasis of number of cells (GO:0048872)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), WD40-repeat domain binding (GO:0071987), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515)

GO Cellular Component (6): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), nuclear matrix (GO:0016363), RNA polymerase II transcription regulator complex (GO:0090575), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Developmental Biology	2
Transcriptional regulation by RUNX1	1
ESR-mediated signaling	1
Hemostasis	1
Gastrulation	1
RNA Polymerase II Transcription	1
Gene expression (Transcription)	1
Generic Transcription Pathway	1
Signaling by Nuclear Receptors	1
Signal Transduction	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
regulation of transcription by RNA polymerase II	3
DNA-templated transcription	3
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
transcription by RNA polymerase II	2
response to stress	2
nuclear lumen	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G1/S phase transition	1
negative regulation of DNA-templated transcription	1
cell cycle	1
mitotic nuclear division	1
response to decreased oxygen levels	1
chordate embryonic development	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
metal ion transport	1
striated muscle cell proliferation	1
cell division	1
lymphocyte differentiation	1
B cell activation	1
myeloid cell differentiation	1
erythrocyte homeostasis	1
positive regulation of biosynthetic process	1
positive regulation of collagen metabolic process	1
collagen biosynthetic process	1
regulation of collagen biosynthetic process	1
positive regulation of apoptotic process	1
regulation of neuron apoptotic process	1
neuron apoptotic process	1
alpha-beta T cell activation involved in immune response	1
T cell differentiation involved in immune response	1
type 2 immune response	1
T-helper cell differentiation	1
megakaryocyte differentiation	1
negative regulation of myeloid cell differentiation	1
regulation of megakaryocyte differentiation	1
negative regulation of RNA biosynthetic process	1

Protein interactions and networks

STRING

2910 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYB	EP300	Q09472	982
MYB	CREBBP	Q92793	954
MYB	MYBBP1A	Q9BQG0	923
MYB	MED15	Q96RN5	841
MYB	CEBPB	P17676	823
MYB	GATA1	P15976	807
MYB	CREB1	P16220	799
MYB	TTF1	Q15361	780
MYB	L3MBTL2	Q969R5	749
MYB	GATA2	P23769	725
MYB	MYC	P01106	696
MYB	SND1	Q7KZF4	691
MYB	CNOT9	Q92600	691
MYB	RUNX1	Q01196	690
MYB	MAT2A	P31153	690

IntAct

65 interactions, top by confidence:

A	B	Type	Score
CLTC	MYB	psi-mi:“MI:0915”(physical association)	0.620
MYB	PAIP1	psi-mi:“MI:0915”(physical association)	0.560
CREBBP	MYB	psi-mi:“MI:0915”(physical association)	0.540
SUMO1	MYB	psi-mi:“MI:0915”(physical association)	0.540
MYB	SUMO2	psi-mi:“MI:0915”(physical association)	0.540
SUMO2	MYB	psi-mi:“MI:0915”(physical association)	0.540
MYB	SUMO1	psi-mi:“MI:0407”(direct interaction)	0.540
MYB	SUMO2	psi-mi:“MI:0407”(direct interaction)	0.540
MYB	LIN9	psi-mi:“MI:0915”(physical association)	0.540
ERC2	MYB	psi-mi:“MI:0915”(physical association)	0.520
Crebbp	MYB	psi-mi:“MI:0915”(physical association)	0.400
TAL1	MYB	psi-mi:“MI:0915”(physical association)	0.400
	MYB	psi-mi:“MI:0915”(physical association)	0.400
MYB		psi-mi:“MI:0915”(physical association)	0.400
MYB	NLK	psi-mi:“MI:0915”(physical association)	0.400
HIPK2	MYB	psi-mi:“MI:0915”(physical association)	0.400
	MYB	psi-mi:“MI:0915”(physical association)	0.370
HLF	MYB	psi-mi:“MI:0915”(physical association)	0.370
MYB	SP100	psi-mi:“MI:0915”(physical association)	0.370
PIAS1	MYB	psi-mi:“MI:0915”(physical association)	0.370
CCND3	MYB	psi-mi:“MI:0915”(physical association)	0.370
MYB	MYOZ2	psi-mi:“MI:0915”(physical association)	0.370
MYB	PPM1K	psi-mi:“MI:0915”(physical association)	0.370
MAPK11	KRT1	psi-mi:“MI:0914”(association)	0.350
	MYB	psi-mi:“MI:0914”(association)	0.350
MYB	A2ML1	psi-mi:“MI:0914”(association)	0.350

BioGRID (180): MYB (Biochemical Activity), MYB (Biochemical Activity), MYB (Reconstituted Complex), MYB (Reconstituted Complex), MYB (Affinity Capture-Western), FBXW7 (Affinity Capture-Western), MYB (Affinity Capture-Western), MYB (Affinity Capture-Western), MYB (Reconstituted Complex), PIAS1 (Reconstituted Complex), MYB (Affinity Capture-Western), TRAF6 (Affinity Capture-Western), MYB (Affinity Capture-Western), UBE2I (Affinity Capture-Western), MYB (Affinity Capture-Western)

ESM2 similar proteins: A0A1W2PPF3, A0A1W2PPM1, A1A546, A1YGI6, A2T763, A5YC49, A6NFQ7, A6NJG6, D2HQI1, G3X9P6, O42173, O57374, P09632, P0C7M4, P10242, P14837, P17278, P31272, P31538, Q1KKS8, Q28ET4, Q28G02, Q3LTE0, Q3UT54, Q4JM65, Q4KL20, Q5TM83, Q5TM84, Q5W1J6, Q68EH7, Q6NSW7, Q80Z64, Q8IUE1, Q8JH55, Q8JIT7, Q8JJ26, Q8MIB7, Q8MIB8, Q8MIE9, Q91685

Diamond homologs: A0A1U8QIH0, A0A1U8QVN4, A0A6S6AAU0, A2WW87, A7SD85, B0G0Y5, B4FNX4, C8VBH3, E0CJS3, F1B281, F4IRB4, K7UPS5, O04192, O13493, O49608, O49782, O80883, P01103, P01104, P04197, P06876, P0CO94, P10242, P10243, P10244, P20025, P22035, P34127, P39964, P46200, P48972, P51960, P52550, P52551, P81393, P81394, P92948, P9WEF9, Q03237, Q05935

SIGNOR signaling

18 interactions.

A	Effect	B	Mechanism
NCL	“down-regulates activity”	MYB	binding
ERK1/2	down-regulates	MYB	phosphorylation
SATB1	“down-regulates quantity by repression”	MYB	“transcriptional regulation”
TWIST2	“down-regulates quantity by repression”	MYB	“transcriptional regulation”
TWIST1	“down-regulates quantity by repression”	MYB	“transcriptional regulation”
ARID5B	“up-regulates quantity by expression”	MYB	“transcriptional regulation”
PML-RARalpha	“up-regulates quantity”	MYB	“transcriptional regulation”
Gbeta	down-regulates	MYB	phosphorylation
HIPK1	“down-regulates activity”	MYB	phosphorylation
NLK	“down-regulates activity”	MYB	phosphorylation
MAPK3	down-regulates	MYB	phosphorylation
MAF	down-regulates	MYB	binding
MYB	“up-regulates quantity by expression”	GSTM1	“transcriptional regulation”
CREBBP	“up-regulates activity”	MYB	binding
MAPK1	unknown	MYB	phosphorylation
CSNK2A1	“down-regulates activity”	MYB	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 46 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SUMOylation of transcription cofactors	5	33.8×	7e-05
Transcriptional regulation by RUNX1	6	24.4×	6e-05
SUMOylation of DNA damage response and repair proteins	5	20.3×	6e-04
Epigenetic regulation of gene expression	6	11.9×	9e-04
Chromatin organization	5	11.3×	2e-03
Chromatin modifying enzymes	5	10.0×	4e-03

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

104 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	62
Likely benign	10
Benign	11

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
495137	t(6;9)(q23.3;p22.3)	Pathogenic
495139	t(6;9)(q23.3;p22.3)	Pathogenic
495140	t(6;9)(q23.3;p22.3)	Pathogenic

SpliceAI

2580 predictions. Top by Δscore:

Variant	Effect	Δscore
6:135185901:A:AG	acceptor_gain	1.0000
6:135185902:G:GG	acceptor_gain	1.0000
6:135186016:AAGAG:A	donor_loss	1.0000
6:135186019:AGG:A	donor_loss	1.0000
6:135186020:GGTAA:G	donor_loss	1.0000
6:135186021:G:A	donor_loss	1.0000
6:135186022:T:G	donor_loss	1.0000
6:135187910:GTTA:G	donor_gain	1.0000
6:135189765:T:TA	acceptor_gain	1.0000
6:135189880:GAGA:G	donor_gain	1.0000
6:135189882:GA:G	donor_gain	1.0000
6:135189884:G:GG	donor_gain	1.0000
6:135192322:A:AG	acceptor_gain	1.0000
6:135192323:G:GG	acceptor_gain	1.0000
6:135192559:G:GG	donor_gain	1.0000
6:135194461:G:GG	donor_gain	1.0000
6:135194950:T:G	acceptor_gain	1.0000
6:135195956:T:G	donor_gain	1.0000
6:135196003:G:GG	donor_gain	1.0000
6:135198901:T:G	acceptor_gain	1.0000
6:135198902:A:AG	acceptor_gain	1.0000
6:135198903:T:G	acceptor_gain	1.0000
6:135198903:TTTA:T	acceptor_loss	1.0000
6:135198905:TA:T	acceptor_loss	1.0000
6:135198906:A:AG	acceptor_gain	1.0000
6:135198907:G:GA	acceptor_gain	1.0000
6:135198907:GT:G	acceptor_gain	1.0000
6:135198907:GTT:G	acceptor_gain	1.0000
6:135198907:GTTC:G	acceptor_gain	1.0000
6:135198907:GTTCT:G	acceptor_gain	1.0000

AlphaMissense

5024 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:135186004:G:C	R42T	1.000
6:135186004:G:T	R42M	1.000
6:135186005:G:C	R42S	1.000
6:135186005:G:T	R42S	1.000
6:135186006:T:A	W43R	1.000
6:135186006:T:C	W43R	1.000
6:135186007:G:C	W43S	1.000
6:135186008:G:C	W43C	1.000
6:135186008:G:T	W43C	1.000
6:135187834:G:C	D48H	1.000
6:135187834:G:T	D48Y	1.000
6:135187835:A:C	D48A	1.000
6:135187835:A:T	D48V	1.000
6:135187844:T:A	L51Q	1.000
6:135187844:T:C	L51P	1.000
6:135187844:T:G	L51R	1.000
6:135187853:T:C	L54P	1.000
6:135187879:T:A	W63R	1.000
6:135187879:T:C	W63R	1.000
6:135187880:G:C	W63S	1.000
6:135187881:G:C	W63C	1.000
6:135187881:G:T	W63C	1.000
6:135187891:G:C	A67P	1.000
6:135187892:C:A	A67D	1.000
6:135187901:T:C	L70P	1.000
6:135189795:G:C	R73P	1.000
6:135189809:T:C	C78R	1.000
6:135189810:G:A	C78Y	1.000
6:135189811:C:G	C78W	1.000
6:135189815:C:G	H80D	1.000

dbSNP variants (sampled 300 via entrez): RS1000154404 (6:135204791 G>A), RS1000191892 (6:135206127 A>AC), RS1000380763 (6:135211659 C>A), RS1000453080 (6:135186605 A>G), RS1000479872 (6:135219403 G>A), RS1000519028 (6:135206566 C>G,T), RS1000616772 (6:135199842 G>A), RS1000752035 (6:135192793 G>A), RS1000937203 (6:135216911 A>T), RS1000984647 (6:135213178 A>C,T), RS1001059748 (6:135184863 A>G), RS1001133971 (6:135199215 T>C), RS1001154677 (6:135206361 G>A), RS1001173570 (6:135186156 C>T), RS1001234649 (6:135186733 T>C)

Disease associations

OMIM: gene MIM:189990 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): adenoid cystic carcinoma (MONDO:0004971)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

85 associations (top):

Study	Trait	p-value
GCST000498_8	Hematological parameters	7.000000e-42
GCST000500_1	Other erythrocyte phenotypes	1.000000e-47
GCST000500_2	Other erythrocyte phenotypes	7.000000e-14
GCST000502_7	Hematocrit	3.000000e-15
GCST000503_12	Mean corpuscular volume	7.000000e-86
GCST000504_8	Mean corpuscular hemoglobin	7.000000e-69
GCST000510_1	Platelet count	1.000000e-09
GCST000532_2	Beta thalassemia/hemoglobin E disease	2.000000e-11
GCST000580_2	Platelet count	3.000000e-14
GCST000582_2	Mean corpuscular hemoglobin concentration	6.000000e-12
GCST000583_5	Hematological and biochemical traits	1.000000e-10
GCST000585_1	Mean corpuscular volume	3.000000e-56
GCST000587_6	Mean corpuscular hemoglobin	3.000000e-66
GCST000588_3	Red blood cell count	7.000000e-48
GCST000589_5	White blood cell count	2.000000e-09
GCST000814_12	Red blood cell traits	3.000000e-15
GCST000814_5	Red blood cell traits	3.000000e-08
GCST000814_6	Red blood cell traits	6.000000e-09
GCST000814_7	Red blood cell traits	1.000000e-08
GCST000814_8	Red blood cell traits	1.000000e-14
GCST000814_9	Red blood cell traits	1.000000e-15
GCST001134_9	White blood cell types	1.000000e-10
GCST001198_59	Multiple sclerosis	2.000000e-06
GCST001337_20	Platelet count	5.000000e-47
GCST001710_1	HbA2 levels	5.000000e-09
GCST001762_505	Obesity-related traits	8.000000e-06
GCST001779_3	Hematology traits	3.000000e-06
GCST001780_6	Mean corpuscular hemoglobin	4.000000e-13
GCST001780_9	Mean corpuscular hemoglobin	4.000000e-15
GCST001781_3	Mean corpuscular volume	2.000000e-09

EFO canonical traits (22, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0004528	mean corpuscular hemoglobin concentration
EFO:0004348	hematocrit
EFO:0004527	mean corpuscular hemoglobin
EFO:0004309	platelet count
EFO:0004509	hemoglobin measurement
EFO:0004842	eosinophil count
EFO:0005845	hemoglobin A2 measurement
EFO:0004730	hormone measurement
EFO:0004541	HbA1c measurement
EFO:0004576	fetal hemoglobin measurement
EFO:0004251	myeloproliferative disorder
EFO:0005090	basophil count
EFO:0007992	basophil percentage of leukocytes
EFO:0007995	basophil percentage of granulocytes
EFO:0004736	aspartate aminotransferase measurement
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0005091	monocyte count
EFO:0007989	monocyte percentage of leukocytes
EFO:0004833	neutrophil count
EFO:0007990	neutrophil percentage of leukocytes

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D003528	Carcinoma, Adenoid Cystic	C04.557.470.200.025.220

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5169115 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

26 potent at pChembl≥5 of 26 total, top 26 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.06	IC50	8.7	nM	CHEMBL321336
8.04	IC50	9.1	nM	CHEMBL228363
7.96	IC50	11	nM	CHEMBL5188413
7.85	IC50	14	nM	CHEMBL5184353
7.85	IC50	14	nM	CHEMBL5198083
7.80	IC50	16	nM	CHEMBL4442805
7.52	IC50	30	nM	CHEMBL5176963
7.52	IC50	30	nM	CHEMBL5176572
7.43	IC50	36.8	nM	CHEMBL5198730
7.40	IC50	40	nM	CHEMBL591374
7.30	IC50	50	nM	CHEMBL5192004
7.22	IC50	60	nM	CHEMBL5203253
7.16	IC50	70	nM	CHEMBL5192001
6.96	IC50	110	nM	CHEMBL5173047
6.89	IC50	130	nM	CHEMBL4436683
6.89	IC50	130	nM	CHEMBL5194887
6.68	IC50	210	nM	CHEMBL4441682
6.62	IC50	240	nM	CHEMBL5187002
6.41	IC50	390	nM	CHEMBL4567907
6.40	IC50	400	nM	CHEMBL5188662
6.40	IC50	400	nM	CHEMBL5179347
6.38	IC50	420	nM	CHEMBL5203497
6.37	IC50	430	nM	CHEMBL4513667
6.00	IC50	1000	nM	CHEMBL4585739
5.50	IC50	3200	nM	CHEMBL4536562
5.43	IC50	3700	nM	CHEMBL1276569

PubChem BioAssay actives

26 with measured affinity, of 32 total; 26 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-amino-4-(3-nitrophenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0087	uM
2-amino-4-(3,4,5-trimethoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0091	uM
2-amino-4-(3,5-dimethoxy-4-prop-2-ynoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0110	uM
2-amino-4-(4-ethoxy-3,5-dimethoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0140	uM
2-amino-4-(3,5-dimethoxy-4-prop-2-enoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0140	uM
2-amino-4-(4-chloro-3-fluorophenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0160	uM
2-amino-4-(4-butoxy-3,5-dimethoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0300	uM
2-amino-4-(3,5-dimethoxy-4-propoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0300	uM
2-amino-4-(3-bromo-4-ethoxy-5-methoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0368	uM
2-amino-4-(3,4-dimethoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0400	uM
2-amino-4-(4-ethoxy-3-iodo-5-methoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0500	uM
2-amino-4-(3,5-dimethoxy-4-propan-2-yloxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0600	uM
2-amino-4-(3,4,5-trifluorophenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.0700	uM
2-amino-4-(4-methoxy-3-nitrophenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.1100	uM
2-amino-4-[3-(pentafluoro-lambda6-sulfanyl)phenyl]-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.1300	uM
2-amino-4-(2-bromo-3,4,5-trimethoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.1300	uM
2-amino-4-(4-methylsulfanylphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.2100	uM
2-amino-4-(3-fluoro-4-methylsulfanylphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.2400	uM
2-amino-4-(4-cyanophenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.3900	uM
2-amino-4-(3,5-dimethoxy-4-pentoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.4000	uM
2-amino-4-(4-methoxy-3-methylphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.4000	uM
2-amino-4-(3-bromo-4-methoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.4200	uM
2-amino-4-(4-methylphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	0.4300	uM
2-amino-4-(3-methoxy-4-phenylmethoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	1.0000	uM
2-amino-4-[4-(pentafluoro-lambda6-sulfanyl)phenyl]-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	3.2000	uM
2-amino-4-(4-methoxyphenyl)-4H-benzo[h]chromene-3-carbonitrile	1875857: Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	ic50	3.7000	uM

CTD chemical–gene interactions

110 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	increases expression, affects cotreatment, decreases expression, decreases reaction, affects expression (+1 more)	13
bisphenol A	affects expression, affects cotreatment, increases methylation, increases expression	7
(+)-JQ1 compound	decreases expression	5
sodium arsenite	decreases expression, increases abundance, increases expression	3
Calcitriol	decreases expression, affects cotreatment	3
Tobacco Smoke Pollution	decreases expression	3
Tretinoin	decreases expression	3
Valproic Acid	affects expression, decreases expression	3
methylmercuric chloride	increases expression	2
Fulvestrant	affects cotreatment, increases methylation, decreases expression	2
Vorinostat	affects cotreatment, decreases expression	2
Glyphosate	decreases expression, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Atrazine	decreases expression, increases expression	2
Benzo(a)pyrene	increases expression, increases methylation	2
Coumestrol	affects cotreatment, increases expression, affects reaction	2
Fluorouracil	affects response to substance, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Aflatoxin B1	increases expression	2
Genistein	increases expression	2
Raloxifene Hydrochloride	increases expression, decreases expression, decreases reaction	2
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
quinone	increases expression, increases reaction, increases activity	1
geraniol	decreases expression	1
sodium arsenate	decreases expression, increases abundance	1
trichostatin A	decreases expression	1
hexamethylene bisacetamide	decreases expression	1
beta-lapachone	decreases expression	1
arsenite	decreases expression, increases abundance	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5131351	Binding	Inhibition of c-Myb (unknown origin) expressed in HEK293T cells measured after 16 hrs by steady-glo luciferase reporter gene assay	A New Naphthopyran Derivative Combines c-Myb Inhibition, Microtubule-Targeting Effects, and Antiangiogenic Properties. — ACS Med Chem Lett

Cellosaurus cell lines

20 cell lines: 8 cancer cell line, 6 embryonic stem cell, 6 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A4H0	SEES3-1V human MYB, clone1	Embryonic stem cell	Male
CVCL_A4H1	SEES3-1V human MYB, clone2	Embryonic stem cell	Male
CVCL_A4H2	SEES3-1V human MYB, clone3	Embryonic stem cell	Male
CVCL_B7TY	CI-huFIB	Transformed cell line	Male
CVCL_B7UE	e-hStr-2	Transformed cell line	Female
CVCL_B7UI	e-hUVEC-1	Transformed cell line
CVCL_B8L1	Abcam HCT 116 MYB KO	Cancer cell line	Male
CVCL_B8Z8	Abcam MCF-7 MYB KO	Cancer cell line	Female
CVCL_B9N8	Abcam A-549 MYB KO	Cancer cell line	Male
CVCL_C4UW	UM-HACC-2A	Cancer cell line	Female

Clinical trials (associated diseases)

59 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00581360	PHASE2	COMPLETED	Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
NCT00886132	PHASE2	COMPLETED	A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
NCT01152840	PHASE2	COMPLETED	Study of RAD001 in Adenoid Cystic Carcinoma
NCT01417143	PHASE2	COMPLETED	Dovitinib in Adenoid Cystic Carcinoma
NCT01524692	PHASE2	COMPLETED	Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma
NCT01558661	PHASE2	COMPLETED	Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
NCT02098538	PHASE2	COMPLETED	Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
NCT02775370	PHASE2	UNKNOWN	A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
NCT02780310	PHASE2	ACTIVE_NOT_RECRUITING	Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT02883374	PHASE2	UNKNOWN	Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety
NCT02942693	PHASE2	UNKNOWN	Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma
NCT03087019	PHASE2	COMPLETED	Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT03639168	PHASE2	COMPLETED	Chidamide Combined With Cisplatin in Head and Neck Adenoid Cystic Carcinoma (HNACC)
NCT03691207	PHASE2	COMPLETED	A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
NCT03990571	PHASE2	COMPLETED	Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT03999684	PHASE2	COMPLETED	A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
NCT04119453	PHASE2	TERMINATED	A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
NCT04209660	PHASE2	ACTIVE_NOT_RECRUITING	Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
NCT04214366	PHASE2	RECRUITING	Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
NCT04291300	PHASE2	COMPLETED	Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients
NCT04832438	PHASE2	WITHDRAWN	9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
NCT04895735	PHASE2	ACTIVE_NOT_RECRUITING	MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
NCT05010629	PHASE2	ACTIVE_NOT_RECRUITING	9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
NCT06199453	PHASE2	WITHDRAWN	The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial
NCT06322576	PHASE2	TERMINATED	177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma
NCT06521775	PHASE2	COMPLETED	An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma
NCT06638931	PHASE2	RECRUITING	Agnostic Therapy in Rare Solid Tumors
NCT06781567	PHASE2	RECRUITING	Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
NCT06805617	PHASE2	RECRUITING	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
NCT06891560	PHASE2	RECRUITING	A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
NCT07162480	PHASE2	RECRUITING	Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I)
NCT07320508	PHASE2	RECRUITING	Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
NCT07521670	PHASE2	NOT_YET_RECRUITING	Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP)
NCT07522879	PHASE2	RECRUITING	A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma
NCT03287427	PHASE1	COMPLETED	MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial
NCT03886831	PHASE1	COMPLETED	A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies
NCT04249947	PHASE1	TERMINATED	P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
NCT04973683	PHASE1	ACTIVE_NOT_RECRUITING	AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
NCT05194072	PHASE1	TERMINATED	A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors